Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice

Clinical and Experimental Immunology

Volumn 106, Issue 2, 1996, Pages 259-264

  Newkirk, M M ^a   Novick, J ^a   Stevenson, M M ^a   Fournier, M J ^a   Apostolakos, P ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

IgG glycosylation; MRL lpr; NOD; rheumatoid factors

Indexed keywords

FC RECEPTOR; GALACTOSE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; SIALIC ACID;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DIABETES MELLITUS; ETIOLOGY; FEMALE; GLYCOSYLATION; HALF LIFE TIME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029850552     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-847.x     Document Type: Article

References (39)

1. Mullinax F, Hymes AJ, Mullinax GL. Molecular site and enzymatic origin of IgG galactose deficiency in rheumatoid arthritis and SLE. Arthritis Rheum 1976; 19:813.
2. Parek RB, Dwek RA, Sutton BJ et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316:452-7.
3. Bond A, Cooke A, Hay FC. Glycosylation of IgG. immune complexes and IgG subclasses in the MRL-lpr-lpr mouse model of rheumatoid arthritis. Eur J Immunol 1990; 20:2229-33.
4. Rademacher TW, Williams P, Dwek RA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA 1994; 91:6123-7.
5. Newkirk M, Fournier M-J, Shiroky J. Rheumatoid factor avidity in patients with rheumatoid arthritis: identification of pathogenic RFs which correlate with disease parameters and with the Gal (0) glyeoform of IgG. J Clin Immunol 1995; 15:250-7.
6. Bond A, Kerr MA, Hay FC. Distinct oligosaccharide content of rheumatoid arthritis-derived immune complexes. Arthritis Rheum 1995; 38:744-9.
7. Bodman KB, Hutchngs PR, Jeddi PA, Delves PJ, Rook GAW, Sumar N, Roitt IM, Lydyard PM. IgG glycosylation in autoimmune-prone strains of mice. Clin Exp Immunol 1994; 95:103-7.
8. Rademacher TW, Parekh RB, Dwek RA et al. The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 1988; 10:231-49.
9. Lunec J, Griffiths HR. Oxygen radicals and agalactosylation of IgG. Glycosyl Dis 1994; 1:212.
10. Axford JS, Lydyard PM, Isenberg DA et al. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet 1987; ii:1486-8.
11. Axford JS, Alavi A, Bond A et al. Differential B lymphocyte galactosyltransferase activity in the MRL mouse model of rheumatoid arthritis. Autoimmunity 1994; 17:157-63.
12. Jeddi PA. Lund T. Modman KB et al. Reduced galactosyltransferase mRNA levels are associated with the agalactosyl IgG found in arthritis-prone MRL-lpr lpr strain mice. Immunology 1984; 83:484-8.
13. Delves PJ, Kiss VJ. The genetic control of glycosylation. In: Isenherg DA, Rademacher TW, eds. Abnormalities of IgG glycosylation and immunological disorders. New York: John Wiley & Sons. Ltd. 1996:171-99.
14. Leatherbarrow RJ, Rademacher TW, Dwek RA. Effector functions of a monoclonal aglysosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol Immunol 1985; 22:407-15.
15. Tao M-H, Morrison SL. Studies of aglycosylated chimeric mouse human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143:2595-601.
16. Lund J, Tanaka T, Takahashi N et al. A protein structural change in aglycosylated IgG3 correlates with loss of huFc (R1 and HuFc (RHI binding and/or activation. Mol Immunol 1990; 27:1145-53.
17. Sandor M, Lynch RG. The biology and pathology of Fc receptors. J Clin Immunol 1993; 13:237-45.
18. Sinclair NR. Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit long-lasting IgG immunological priming after removal of the Fc fragment. J Exp Med 1969; 129:1183-201.
19. van de Winkel JGJ, Capel PJA. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14:215-21.
20. Poljak RJ. Crystallization of immunoglobulins and their fragments for x-ray diffraction studies. Methods Enzymol 1985; 116:190-200.
21. Stevenson MM, Tam MF, Belosevic M et al. Role of endogenous gamma interferon in host response to infection with blood-stage Plasmodium chabaudi AS. Infect Immun 1990; 58:3225-32.
22. Sivo J, Politis AD, Vogel SN. Differential effects of interferon-γ and glucocorticoids on FcγR gene expression in murine macrophages. J Leuk Biol 1993; 54:451-7.
23. H2 domains. Mol Immunol 1992; 29:213-20.
24. Wawrznczak EJ, Denham S, Parnell GD et al. Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting C1q and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse. Mol Immunol 1992; 29: 221-7.
25. H2-associaled carbohydrate structure on the functional properties and in vivo fate of chimeric mouse human immunoglobulin G1. J Exp Med 1994; 180:1087-96.
26. Harrison PT, Davis W, Norman JC et al. Binding of monomeric immunoglobulin G triggers FcγRU-mediated endocytosis. J Biol Chem 1994; 269:24396-402.
27. Prins JB, Todd JA, Rodrigues NR et al. Linkage on chromosome 3 of autoimmune diabetes and detective Fc receptor for IgG in NOD mice. Science 1993; 260:695-8.
28. Davis WD, Harrison T, Hutchison MJ et al. Two distinct regions of FcγRI initiate separate signalling pathways involved in endocytosis and phagocytosis. EMBO J 1995; 14:432-41.
29. Malhotra R, Wormald MR, Rudd PM et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Med 1995; 1:237-43.
30. Rabinovitch A, Suarez-Pinzon WL, Sorensen O et al. IFN-γ gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol 1995; 154:4874-82.
31. Aguado MT, Balderas RS, Rubin RL et al. Specificity and molecular characteristics of monoclonal IgM rheumatoid factors from arthritic and non-arthritic mice. J Immunol 1987; 139:1080-7.
32. Tarkowski A, Czerkinsky C, Nilsson LA. Detection of IgG rheumatoid factor secreting cells in autoimmune MRL/1 mice: a kinetic study. Clin Exp Immunol 1984; 58:7-12.
33. Bond A, Cooke A, Hay FC. Heterogeneity in rheumatoid factor isotypes and specificities in MRL mice. Immunology 1988; 64:17-21.
34. Berney T, Fulpius T, Shibata T et al. Selective pathogenicity of murine rheumatoid factors of the cryoprecipitable IgG3 subclass. Int Immunol 1991; 4:93-99.
35. Shibata T, Berney T, SpertiniF, Izui S. Rheumatoid factors in mice bearing the lpr or gld mutation. Selective production of rheumatoid factor cryoglobulins in MRL/MPJ-lpr/lpr mice. Clin Exp Immunol 1992; 87:190-5.
36. Sobel ES, Katagiri T, Karagiri K et al. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 1992; 173:1441-9.
37. Newkirk MM. Fe glycosylation and rheumatoid factors. In: Isenberg DA, Rademacher TW, eds. Abnormalities of IgG glycosylation and immunological disorders. New York: John Wiley & Sons. Ltd. 1996:119-30.
38. Humphreys-Beher MG, Brinkley L, Purushotham KR et al. Characterisation of antinuclear autoantibodies present in the serum from nonobese diabetic (NOD) mice. Clin Immunol Immunopathol 1993; 68:350-5.
39. Humphreys-Beher MG, Hu Y, Nakagawa Y et al. Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjögren's syndrome. Adv Exp Med Biol 1994; 350:631-6.